Skip to main content

Table 1 Patient and tumour characteristic by p16 expression status

From: Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer

 

p16 Negative

p16 Positive

 

Patient/Tumour Data

No.

%

No.

%

p

Nº of patients

90

18

 

Age, years

   

   Median

59

57

NS

   Range

33-84

44-77

 

Sex

     

   Male

84

93

17

94

NS

   Female

6

7

1

6

 

Current smokers

     

   No

3

3

3

16

 

   Yes

67

74

10

55

0.01

Unknown

20

23

5

29

 

Alcohol consumption

     

   No

10

11

3

16

 

   Yes

57

63

10

55

NS

Unknown

23

26

5

29

 

Performance status

     

   ECOG 0

36

40

9

50

NS

   ECOG 1

43

48

8

44

 

   ECOG 2

11

12

1

6

 

Tumor site

     

   Oral cavity

14

16

2

11

0.04

   Oropharynx

30

33

9

50

 

   Larynx

36

40

2

11

 

   Hypopharynx

10

11

5

28

 

PCR - HPV status

     

HR-HPV (16,18,51,58)

8

9

9

50

 

LR-HPV (5,6)

2

2

1

5.5

0.0001

Unknown subtype

1

1

1

5.5

 

Negative

79

88

7

39

 

Grade

     

   Well/Moderate

40

44

6

33

NS

   Poor

9

10

2

11

 

   Unknown

41

46

10

56

 

Tumour stage

     

   T1-T3

37

41

5

28

NS

   T4

53

59

13

72

 

Nodal status

     

   No

28

31

5

28

NS

   N+

62

69

13

72

 

Stage

     

III

28

31

6

33

NS

IV

62

59

12

67

 

Treatment

     

RT-CT

46

51

10

56

NS

RT-EGFR inhibitors

44

49

8

44

 

Irradiation dose

     

Mean

71

 

71.4

 

NS

Range

57-78

 

70-74

  

Type of radiotherapy

     

Conventional RT

11

12

0

0

NS

Concomitant boost

79

88

18

100

 

Response

     

Complete response

67

74

16

89

 

Partial response

16

18

0

0

NS

Stable disease

1

1

1

5.5

 

Progression

0

0

1

5.5

 

Unknown

6

7

0

0

 

Median OS (months)

32

 

54

 

NS

Range

14-50

 

20-87

  

Median DFS (months)

18

 

52

 

NS

Range

13-24

 

0-103

  
  1. Abbreviation: NS, not significant.